[go: up one dir, main page]

PE20060486A1 - Derivados de pirrol-oxindol como moduladores del receptor de progesterona - Google Patents

Derivados de pirrol-oxindol como moduladores del receptor de progesterona

Info

Publication number
PE20060486A1
PE20060486A1 PE2005000785A PE2005000785A PE20060486A1 PE 20060486 A1 PE20060486 A1 PE 20060486A1 PE 2005000785 A PE2005000785 A PE 2005000785A PE 2005000785 A PE2005000785 A PE 2005000785A PE 20060486 A1 PE20060486 A1 PE 20060486A1
Authority
PE
Peru
Prior art keywords
pirrol
pyrrol
carbonitrile
indol
oxo
Prior art date
Application number
PE2005000785A
Other languages
English (en)
Inventor
Michael Anthony Marella
Gary Sondermann Grubb
Casey Cameron Mccomas
Jay Edward Wrobel
Edward George Melenski
Andrew Fensome
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060486A1 publication Critical patent/PE20060486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS PIRROL-OXINDOLES DE FORMULA (I), EN DONDE R1 ES H, ALQUILO OPCIONALMENTE SUSTITUIDO, CICLOALQUILO, ENTRE OTROS; R2 Y R3 SON INDEPENDIENTEMENTE H, ALQUILO, O JUNTOS FORMAN UN ANILLO Y CONTIENEN -CH2-(CH2)n-CH2-; n ES 1 0 2; R4 Y R6 ES H O HALOGENO; R5 Y R8 ES H; R7 ES H, ENTRE OTROS; R9 ES H, ALQUILO OPCIONALMENTE SUSTITUIDO CON RA, EL CUAL ES ALQUILO OPCIONALMENTE SUSTITUIDO TAL COMO TER-BUTILO. SON PREFERIDOS: 5-(7-FLUORO-3,3-DIMETIL-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)-1-METIL-1H-PIRROL-2-CARBONITRILO, 5-(7'-FLUORO-2'-OXO-1',2'-DIHIDROESPIRO[CICLOBUTAN-1,3'-INDOL]-5'-IL)-1-METIL-1H-PIRROL-2-CARBONITRILO, 5-(4-FLUORO-3,3-DIMETIL-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)-1-METIL-1H-PIRROL-2-CARBONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA, UN KIT Y A UN PROCESO DE ELABORACION. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE PROGESTERONA, POR LO QUE SON UTILES COMO ANTICONCEPTIVOS, TERAPIA DE REEMPLAZO HORMONAL, NEOPLASIA HORMONAL, DISMENORREA O SINTOMAS RELACIONADAS CON EL CICLO MENSTRUAL
PE2005000785A 2004-08-09 2005-07-06 Derivados de pirrol-oxindol como moduladores del receptor de progesterona PE20060486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60003104P 2004-08-09 2004-08-09
US67168405P 2005-04-15 2005-04-15

Publications (1)

Publication Number Publication Date
PE20060486A1 true PE20060486A1 (es) 2006-07-06

Family

ID=34979790

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000785A PE20060486A1 (es) 2004-08-09 2005-07-06 Derivados de pirrol-oxindol como moduladores del receptor de progesterona

Country Status (20)

Country Link
US (2) US7317037B2 (es)
EP (1) EP1776107A1 (es)
JP (1) JP2008509217A (es)
KR (1) KR20070039567A (es)
AR (1) AR049706A1 (es)
AU (1) AU2005277881A1 (es)
BR (1) BRPI0514180A (es)
CA (1) CA2573314A1 (es)
CR (1) CR8847A (es)
EC (1) ECSP077233A (es)
GT (1) GT200500185A (es)
IL (1) IL181043A0 (es)
MX (1) MX2007001608A (es)
NO (1) NO20070742L (es)
PA (1) PA8638801A1 (es)
PE (1) PE20060486A1 (es)
RU (1) RU2007101303A (es)
SV (1) SV2006002167A (es)
TW (1) TW200607798A (es)
WO (1) WO2006023109A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
CN1980676A (zh) 2004-07-07 2007-06-13 惠氏公司 周期性黄体酮方案及试剂盒
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US8343965B2 (en) * 2005-04-28 2013-01-01 Wyeth Llc Compositions containing micronized tanaproget prepared by wet granulation
CN101166532B (zh) 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
ES2340518T3 (es) * 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US20080051585A1 (en) * 2006-08-17 2008-02-28 Wyeth Process for the preparation of indolin-2-one derivatives useful as PR modulators
CN101631546A (zh) 2006-10-12 2010-01-20 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
WO2008153674A1 (en) * 2007-06-09 2008-12-18 Boris Kobrin Method and apparatus for anisotropic etching
US20080312306A1 (en) * 2007-06-15 2008-12-18 Wyeth Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile
US20080319204A1 (en) * 2007-06-25 2008-12-25 Wyeth Process for the synthesis of progesterone receptor modulators
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
AU2009303468B2 (en) 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN101417945B (zh) * 2008-10-23 2012-05-23 浙江工业大学 4-溴-2,3,5,6-四氟苯乙酸的制备方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
IN2014DN10548A (es) 2012-05-31 2015-08-21 Repros Therapeutics Inc
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
AU2013338305B2 (en) 2012-11-02 2018-06-07 Allergan pharmaceuticals International Ltd. Methods and compositions for treating progesterone-dependent conditions
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6301076B2 (ja) * 2013-07-11 2018-03-28 キヤノンメディカルシステムズ株式会社 核医学診断装置および画像処理プログラム
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CN105294659A (zh) * 2014-07-01 2016-02-03 中国科学院成都有机化学有限公司 3,3’-二取代的3-吡咯氧化吲哚化合物及其不对称合成方法
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2601749C1 (ru) * 2015-09-08 2016-11-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения 4'-фторспиро[циклопропан-1,3'-индол]-2'(1'н)-она
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US9797043B1 (en) * 2016-09-13 2017-10-24 Rohm And Haas Electronic Materials Llc Shielding coating for selective metallization
CN110845390B (zh) * 2019-11-26 2023-04-07 郑州师范学院 一种3-氟氧化吲哚衍生物的制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103752D0 (sv) 1991-12-18 1991-12-18 Astra Ab New compounds
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
CN1324355A (zh) 1998-10-22 2001-11-28 西巴特殊化学品控股有限公司 氧代苯并呋喃亚基－二氢吲哚酮
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US20020128208A1 (en) 2000-12-15 2002-09-12 Snyder James P. Nonpeptide agonists and antagonists of vasopressin receptors
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
JP2005527553A (ja) 2002-03-29 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 自己免疫疾患の治療におけるスタチン類および他の自己免疫調節剤の利用
BR0312092A (pt) 2002-06-25 2005-03-22 Wyeth Corp Uso de derivados de tio-oxindol no tratamento de distúrbios da pele
TW200407124A (en) 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
WO2004037853A2 (en) 2002-10-21 2004-05-06 Irm Llc Quinolones with anti-hiv activity
MXPA05003658A (es) 2002-10-28 2005-06-08 Warner Lambert Co Derivados de piperazina sustituidos con oxindol.
EP1625099A2 (en) * 2003-04-01 2006-02-15 Corning Incorporated Lamp reflector substrate, glass, glass-ceramic materials and process for making the same
PL1732921T3 (pl) 2004-04-08 2009-04-30 Wyeth Corp Pochodne tioamidu jako modulatory receptora progesteronowego
FR2868775B1 (fr) 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PE20060331A1 (es) 2004-04-27 2006-05-16 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
WO2005104711A2 (en) 2004-04-27 2005-11-10 Wyeth Purification of progesterone receptor modulators
US20050261327A1 (en) 2004-05-20 2005-11-24 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation
GT200500186A (es) * 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
CN1980676A (zh) * 2004-07-07 2007-06-13 惠氏公司 周期性黄体酮方案及试剂盒
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
KR20070085340A (ko) 2004-10-12 2007-08-27 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물

Also Published As

Publication number Publication date
TW200607798A (en) 2006-03-01
RU2007101303A (ru) 2008-09-20
SV2006002167A (es) 2006-03-15
US20080114050A1 (en) 2008-05-15
AR049706A1 (es) 2006-08-30
BRPI0514180A (pt) 2008-06-03
IL181043A0 (en) 2007-07-04
WO2006023109A1 (en) 2006-03-02
MX2007001608A (es) 2007-04-10
US7317037B2 (en) 2008-01-08
US20060030717A1 (en) 2006-02-09
ECSP077233A (es) 2007-03-29
CA2573314A1 (en) 2006-03-02
EP1776107A1 (en) 2007-04-25
NO20070742L (no) 2007-05-07
PA8638801A1 (es) 2006-06-02
AU2005277881A1 (en) 2006-03-02
JP2008509217A (ja) 2008-03-27
KR20070039567A (ko) 2007-04-12
CR8847A (es) 2007-08-28
GT200500185A (es) 2006-04-10

Similar Documents

Publication Publication Date Title
PE20060486A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
PE20040570A1 (es) Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
CO6260060A2 (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
AR032128A1 (es) Compuestos moduladores del receptor glucocorticoide, uso de los mismos en fabricacion de medicamentos, composiciones, y conjuntos intermediarios y proceso de preparacion
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR045762A1 (es) Derivados de quinazolina
CR7514A (es) Derivados del tropano como moduladores de ccr5
PE20020583A1 (es) Derivados de benzodiazepina como moduladores del receptor gaba a
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
PE20050961A1 (es) Compuestos de imidazopiridina tropano sustituidos como antagonistas del receptor ccr5
ES2423668T3 (es) Moduladores de receptores 5-HT y métodos de uso de los mismos
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR049664A1 (es) Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits.
PE20231215A1 (es) Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina

Legal Events

Date Code Title Description
FD Application declared void or lapsed